Literature DB >> 30635094

Macrophages: Their Untold Story in T Cell Activation and Function.

Jennifer L Guerriero1.   

Abstract

The complexity of T cell activation to maintain homeostasis and provide host defense is highlighted by the intricate step-wise process which is coordinated by multiple cell types. Crucial to T cell activation is the requirement of antigen-presenting cells (APCs) such as macrophages at each step of the activation and effector stages. Macrophages are central regulators in T cell activation and are involved in each step including initiating the series of events leading to T cell activation. Macrophages identify and present foreign antigens in classes I and II major histocompatibility complexes (MHC) to T cells, which recognize the MHC-antigen complex through their T cell receptor. This initial step is all in vain if additional costimulatory and cytokine signaling does not occur concurrently. Macrophages can mediate and provide the required costimulatory signaling and cytokine secretion required for effective T cell activation. While other cell types, especially other APCs, may be capable of playing a role during different stages of T cell activation, this review will focus on how macrophages can modulate T cell activation and effector function. This is in no way an attempt to minimize the role of other APCs but instead to bring to light to the role macrophages can play during this process. Here, the role macrophages play in cancer to either activate or inhibit T cells based on macrophage phenotype, costimulatory molecules, and cytokine secretion is highlighted as an example of how macrophages can significantly alter T cell activation and effector function in human disease.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antigen presentation; Antigen-presenting cells; Macrophage; Major histocompatibility complex; T cell; T cell receptor; Tumor-associated macrophage

Year:  2018        PMID: 30635094     DOI: 10.1016/bs.ircmb.2018.07.001

Source DB:  PubMed          Journal:  Int Rev Cell Mol Biol        ISSN: 1937-6448            Impact factor:   6.813


  36 in total

1.  The immunotherapy revolution in genitourinary malignancies.

Authors:  Shruti U Gandhy; Ravi A Madan; Jeanny B Aragon-Ching
Journal:  Immunotherapy       Date:  2020-06-29       Impact factor: 4.196

Review 2.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

3.  The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1.

Authors:  Hongzhong Li; Yi Xiao; Qin Li; Jun Yao; Xiangliang Yuan; Yuan Zhang; Xuedong Yin; Yohei Saito; Huihui Fan; Ping Li; Wen-Ling Kuo; Angela Halpin; Don L Gibbons; Hideo Yagita; Zhongming Zhao; Da Pang; Guosheng Ren; Cassian Yee; J Jack Lee; Dihua Yu
Journal:  Cancer Cell       Date:  2021-11-24       Impact factor: 31.743

4.  Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer.

Authors:  Kelly Kersten; Kenneth H Hu; Alexis J Combes; Bushra Samad; Tory Harwin; Arja Ray; Arjun Arkal Rao; En Cai; Kyle Marchuk; Jordan Artichoker; Tristan Courau; Quanming Shi; Julia Belk; Ansuman T Satpathy; Matthew F Krummel
Journal:  Cancer Cell       Date:  2022-05-26       Impact factor: 38.585

Review 5.  Immunomodulation by anticancer cell cycle inhibitors.

Authors:  Giulia Petroni; Silvia C Formenti; Selina Chen-Kiang; Lorenzo Galluzzi
Journal:  Nat Rev Immunol       Date:  2020-04-28       Impact factor: 53.106

Review 6.  Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer.

Authors:  Anita K Mehta; Sapana Kadel; Madeline G Townsend; Madisson Oliwa; Jennifer L Guerriero
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

7.  MicroRNA-22 represses glioma development via activation of macrophage-mediated innate and adaptive immune responses.

Authors:  Jiajie Tu; Yilong Fang; Dafei Han; Xuewen Tan; Zhen Xu; Haifeng Jiang; Xinming Wang; Wenming Hong; Wei Wei
Journal:  Oncogene       Date:  2022-03-12       Impact factor: 9.867

Review 8.  Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells.

Authors:  Yoshiko Matsuda; Takeshi Watanabe; Xiao-Kang Li
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

Review 9.  Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1.

Authors:  Hao Cai; Yichi Zhang; Jian Wang; Jinyang Gu
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

Review 10.  Calreticulin and cancer.

Authors:  Jitka Fucikova; Radek Spisek; Guido Kroemer; Lorenzo Galluzzi
Journal:  Cell Res       Date:  2020-07-30       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.